bluebird bio, Inc. (0HOH.L)
USD 9.28
(33.91%)
USD 9.28
(33.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 108.57 Million USD | -35.52% |
| 2022 | 168.38 Million USD | 335.25% |
| 2021 | -71.57 Million USD | 42.59% |
| 2020 | -124.68 Million USD | 8.47% |
| 2019 | -136.22 Million USD | 45.03% |
| 2018 | -247.83 Million USD | 58.88% |
| 2017 | -602.7 Million USD | -279.66% |
| 2016 | -158.74 Million USD | -55.07% |
| 2015 | -102.36 Million USD | 70.57% |
| 2014 | -347.84 Million USD | -68.63% |
| 2013 | -206.27 Million USD | -207.83% |
| 2012 | -67.01 Million USD | -161.72% |
| 2011 | -25.6 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 202.29 Million USD | 86.33% |
| 2024 Q2 | 246.35 Million USD | 21.78% |
| 2023 Q4 | 108.57 Million USD | -21.53% |
| 2023 Q3 | 138.36 Million USD | 3.27% |
| 2023 Q2 | 133.98 Million USD | 290.29% |
| 2023 Q1 | 34.33 Million USD | -79.61% |
| 2023 FY | 108.57 Million USD | -35.52% |
| 2022 Q4 | 168.38 Million USD | -20.47% |
| 2022 Q2 | 211.46 Million USD | 5085.61% |
| 2022 Q1 | 4.07 Million USD | 105.7% |
| 2022 FY | 168.38 Million USD | 335.25% |
| 2022 Q3 | 211.73 Million USD | 0.13% |
| 2021 Q1 | -233.94 Million USD | -87.63% |
| 2021 Q2 | -154.86 Million USD | 33.8% |
| 2021 FY | -71.57 Million USD | 42.59% |
| 2021 Q3 | -220.89 Million USD | -42.64% |
| 2021 Q4 | -71.57 Million USD | 67.6% |
| 2020 Q4 | -124.68 Million USD | 3.25% |
| 2020 Q3 | -128.87 Million USD | 87.15% |
| 2020 Q1 | -146.28 Million USD | -7.38% |
| 2020 Q2 | -1 Billion USD | -585.81% |
| 2020 FY | -124.68 Million USD | 8.47% |
| 2019 Q2 | -86.77 Million USD | -141.22% |
| 2019 FY | -136.22 Million USD | 45.03% |
| 2019 Q4 | -136.22 Million USD | -30.4% |
| 2019 Q3 | -104.46 Million USD | -20.39% |
| 2019 Q1 | -35.97 Million USD | 85.49% |
| 2018 Q1 | -300.94 Million USD | 50.07% |
| 2018 FY | -247.83 Million USD | 58.88% |
| 2018 Q4 | -247.83 Million USD | 68.91% |
| 2018 Q3 | -797.1 Million USD | -346.23% |
| 2018 Q2 | -178.63 Million USD | 40.64% |
| 2017 Q1 | -68.44 Million USD | 56.88% |
| 2017 Q2 | -532.37 Million USD | -677.8% |
| 2017 FY | -602.7 Million USD | -279.66% |
| 2017 Q4 | -602.7 Million USD | -626.97% |
| 2017 Q3 | -82.9 Million USD | 84.43% |
| 2016 Q3 | -145.16 Million USD | -6.74% |
| 2016 Q4 | -158.74 Million USD | -9.36% |
| 2016 Q1 | -118.17 Million USD | -15.44% |
| 2016 Q2 | -136 Million USD | -15.09% |
| 2016 FY | -158.74 Million USD | -55.07% |
| 2015 Q2 | -593.29 Million USD | -345.51% |
| 2015 Q3 | -373.73 Million USD | 37.01% |
| 2015 Q4 | -102.36 Million USD | 72.61% |
| 2015 Q1 | -133.17 Million USD | 61.71% |
| 2015 FY | -102.36 Million USD | 70.57% |
| 2014 Q3 | -89.6 Million USD | 49.01% |
| 2014 Q1 | -192.49 Million USD | 6.68% |
| 2014 Q4 | -347.84 Million USD | -288.21% |
| 2014 Q2 | -175.71 Million USD | 8.72% |
| 2014 FY | -347.84 Million USD | -68.63% |
| 2013 Q2 | -228.84 Million USD | -73.58% |
| 2013 FY | -206.27 Million USD | -207.83% |
| 2013 Q4 | -206.27 Million USD | 4.85% |
| 2013 Q3 | -216.79 Million USD | 5.27% |
| 2013 Q1 | -131.83 Million USD | -96.74% |
| 2012 FY | -67.01 Million USD | -161.72% |
| 2012 Q4 | -67.01 Million USD | 0.0% |
| 2011 FY | -25.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 224.628% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1.816% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 423.832% |
| Perrigo Company plc | 3.32 Billion USD | 96.732% |
| Illumina, Inc. | 1.21 Billion USD | 91.057% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.595% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 195.331% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 98.682% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.155% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 25.163% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 500.631% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1410.658% |
| Waters Corporation | 1.96 Billion USD | 94.462% |
| Biogen Inc. | 6.28 Billion USD | 98.273% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 1629.169% |
| Evolus, Inc. | 63.7 Million USD | -70.42% |
| Adicet Bio, Inc. | -142 Million USD | 176.454% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1304.204% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 76.331% |
| FibroGen, Inc. | 56.76 Million USD | -91.257% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 90.518% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1458.12% |
| Homology Medicines, Inc. | 18.43 Million USD | -488.876% |
| Geron Corporation | 14.76 Million USD | -635.526% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 93.152% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 45.184% |
| Myriad Genetics, Inc. | 88.1 Million USD | -23.236% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 300.109% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 197.459% |
| Zoetis Inc. | 4.76 Billion USD | 97.72% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 1178.056% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 94.825% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 71.334% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.135% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 845.066% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 89.702% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -240.508% |
| Verastem, Inc. | -37.27 Million USD | 391.247% |
| Nektar Therapeutics | 210.24 Million USD | 48.359% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 154.334% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 394.998% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 88.788% |
| OPKO Health, Inc. | 230.68 Million USD | 52.935% |
| Exelixis, Inc. | -73.05 Million USD | 248.626% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 38.764% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 180.185% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 171.89% |
| uniQure N.V. | -102.95 Million USD | 205.459% |
| Imunon, Inc. | -4.69 Million USD | 2410.379% |
| Blueprint Medicines Corporation | 702.83 Million USD | 84.552% |
| Insmed Incorporated | 721.62 Million USD | 84.955% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 92.138% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 447.794% |
| TG Therapeutics, Inc. | 17.86 Million USD | -507.832% |
| Incyte Corporation | -3.17 Billion USD | 103.419% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 85.823% |